Results 151 to 160 of about 873,692 (294)
Unlocking the Power of ORCID Integrations
, 2018 Gabriela Mejías, Mejias, Gabriela
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi +12 more
wiley +1 more source
ORCID: Persistent IDs in a World Where Machines Aid Research
, 2018 Brian Minihan, Minihan, Brian
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro +17 more
wiley +1 more source
Implementing your ORCID Plugin for OJS/OPS? Help is Here.
, 2021 Alejandra Casas Niño de Rivera
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli +4 more
wiley +1 more source
CONCYTEC-ORCID: ORCID para investigadores Renacyt, grupo "María Rostworowski"
, 2020 Ana Heredia +2 more
openalex +1 more source
Ongoing ORCID implementation within pharmaceutical industry: an Open Pharma and GSK Vaccines initiative [PDF]
, 2018 Santosh G. Mysore +7 more
openalex +1 more source